E&C Advances Bills Restricting CMS' NCD Authority, Hiking Oversight

By Luke Zarzecki, Jessica Karins / December 7, 2023 at 10:54 AM
The House Energy & Commerce Committee voted to advance three bills that aim to limit the scope of CMS’ national and local coverage determinations, aiming to give patients more access to novel treatments, following congressional backlash to CMS’ attempt to limit coverage of pricey and controversial anti-amyloid Alzheimer’s disease drugs. One of the bills would prevent from prevent CMS from again imposing a national coverage determination (NCD) on a whole class of drugs, as it did in the case of...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.